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Abstract
Background: In critically ill (preterm) neonates, central venous catheters (CVCs) are increasingly used for administration
of medication or parenteral nutrition. A serious complication, however, is the development of catheter-related thrombosis
(CVC-thrombosis), which may resolve by itself or cause severe complications. Due to lack of evidence, management of
neonatal CVC-thrombosis varies among neonatal intensive care units (NICUs). In the Netherlands an expert-based national
management guideline has been developed which is implemented in all 10 NICUs in 2014.
Methods: The NEOCLOT study is a multicentre prospective observational cohort study, including 150 preterm and term
infants (0-6 months) admitted to one of the 10 NICUs, developing CVC-thrombosis. Patient characteristics, thrombosis
characteristics, risk factors, treatment strategies and outcome measures will be collected in a web-based database.
Management of CVC-thrombosis will be performed as recommended in the protocol. Violations of the protocol will be
noted. Primary outcome measures are a composite efficacy outcome consisting of death due to CVC-thrombosis and
recurrent thrombosis, and a safety outcome consisting of the incidence of major bleedings during therapy. Secondary
outcomes include individual components of primary efficacy outcome, clinically relevant non-major and minor
bleedings and the frequency of risk factors, protocol variations, residual thrombosis and post thrombotic syndrome.
Discussion: The NEOCLOT study will evaluate the efficacy and safety of the new, national, neonatal CVC-thrombosis
guideline. Furthermore, risk factors as well as long-term consequences of CVC-thrombosis will be analysed.
Trial registration: Trial registration: Nederlands Trial Register NTR4336. Registered 24 December 2013.
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Background
In critically ill (preterm) neonates, central venous cathe-
ters (CVCs) are increasingly used for administering
medication or parenteral nutrition. These catheters are
inserted in umbilical veins, major central veins or in
smaller peripheral veins. CVCs are one of the stepping
stones in improvement of care for critically ill neonates.
However, one of the complications associated with CVC
usage is venous thrombosis. The prevalence of neonatal
CVC-related thrombosis (CVC-thrombosis) varies from
0.7% to 67% and is dependent on the type of catheter
inserted, the diagnostic tests used, the study method and
the index of suspicion of thrombosis [1–3].
Evidence in literature on optimal management of
neonates with CVC-thrombosis is lacking [4]. Only case-
series and case reports are available. Therapeutic options
include 1) a “wait and see” policy (an expectative policy
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monitored with ultrasonography), 2) anticoagulant treat-
ment, 3) thrombolysis, and 4) thrombectomy [4].
The “wait and see” policy
The “wait and see” policy might be an option as
spontaneous regression of CVC-thrombosis has been de-
scribed. Butler-O’Hara et al. reported spontaneous regres-
sion in 13 of 24 children with umbilical venous catheter
thrombosis after a median duration of 28 days, without
anticoagulation [5]. Small retrospective studies confirmed
this observation [3, 6]. In addition, Kim et al. prospectively
studied the incidence of neonatal portal venous throm-
bosis associated with catheterization of the umbilical vein.
Ultrasonography demonstrated asymptomatic portal
venous thrombosis in 43 of 100 neonates. Follow-up ultra-
sonography showed complete or partial resolution in 20
(56%) of 36 neonates without treatment. A significant
negative relationship was found between the initial size of
thrombosis and spontaneous clot resolution [7].
On the other hand, CVC-thrombosis may increase in
size and cause potential life-threatening acute and/or
chronic complications [8]. CVC-thrombosis in the right
atrium may lead to tricuspid valve obstruction, pulmon-
ary embolism with severe respiratory insufficiency and
heart failure. Cerebral embolism via a patent foramen
ovale may cause stroke [9]. The exact prevalence of
these complications remains unknown. However, the po-
tential life threatening character of these complications
warrant the use of antithrombotic measures, including
anticoagulants, thrombolysis and thrombectomy.
Anticoagulant treatment
Little is known about the efficacy and safety of anticoagu-
lant and thrombolytic agents in neonates. To the best of
our knowledge, no randomized controlled trials have been
conducted to date. Low molecular weight heparin
(LMWH) is the most prescribed anticoagulant agent in ne-
onates [4, 10]. In adults, LMWH is as effective as unfractio-
nated heparin (UFH) with decreased risk of bleeding
complications and heparin-induced thrombocytopenia [11].
The pharmacokinetics of LMWH are more predictable
than those of UFH, resulting in less frequent dose adjust-
ments and monitoring to achieve the therapeutic range. In
addition, LMWH can be administered subcutaneously,
once or twice daily. In children, therefore, LMWH as enox-
aparin has already become the agent of choice in treatment
of thrombosis [12].
Malowany et al. reviewed all studies between 1980 and
2007 in which enoxaparin was used to treat neonates.
Enoxaparin was administered to 240 neonates (53 pre-
term, 61 term and 126 neonates with unknown gesta-
tional age) with venous thrombosis. Preterm neonates
required a higher dose of enoxaparin than term
neonates. A starting dose of 1.7 mg/kg enoxaparin per
12 h in term and 2 mg/kg enoxaparin per 12 h in pre-
term neonates is suggested: Eighty-six of 119 neonates
(72%) demonstrated complete or partial resolution of
thrombosis. The overall major bleeding rate was 4% (9
of 217 neonates) [11]. In later studies, reported bleeding
rate raged from 0 to 4% [13–16].
Thrombolytic treatment
Three thrombolytic agents are available, i.e. streptokinase,
urokinase and recombinant tissue plasminogen activator
(r-tPA). In contrast to streptokinase and urokinase, r-tPA
has an increased affinity for fibrin-bound plasminogen,
which theoretically makes the drug more effective near
the thrombus than streptokinase or urokinase, whilst also
potentially lowering the risk of bleeding. However, no in
vivo studies have been carried out to support the theorised
advantage of r-tPA. In general, r-tPA is most frequently
used for thrombolysis in children. In a literature review,
Torres-Valdivieso et al. reviewed literature and analyzed
98 neonates treated with varying doses of r-tPA [17]. The
clot completely resolved in 70%, it partially disappeared in
20% and remained unaffected in 10% of the patients.
However, the complication rate was high: 4% of neonates
died as a result of major bleeding, 10% experienced intra-
ventricular bleeding, 2% suffered pulmonary bleeding, 1%
had kidney bleeding and 5% had minor bleeding [17]. The
precise r-tPA dosage for thrombolysis in neonates is un-
known. In vitro studies have demonstrated that neonates
are slow responders to fibrinolytic drugs, which might be
explained by lower plasminogen plasma values than in
adults. Adding plasma has been shown to accelerate the fi-
brinolytic process [18].
Thrombectomy
Thrombectomy is the fourth therapeutic option in neo-
natal thrombosis. However, in neonates thrombectomy
is usually impossible due to the small calibre of the
vessels. Additionally, re-occlusion occurs frequently. Sur-
gical thrombectomy of the thrombus in the right atrium
is a highly invasive and dangerous procedure. Only a few
case reports are available in neonates [6, 8].
National guideline
How to choose between the four therapeutic options in
neonates with thrombosis? The American College of
Chest Physicians (ACCP) evidence-based guideline of
2012 recommends either to treat neonatal CVC-
thrombosis with anticoagulants and/or to monitor it
with ultrasonography [4]. Anticoagulant agents should
be administered if extension of thrombosis occurs. The
ACCP guideline discourages thrombolytic therapy for
neonatal CVC-thrombosis unless major vein occlusion is
causing critical comprise of organs or limbs. Yang et al.
tried to outline high-risk right atrial thrombosis in a
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literature review of 122 neonates and children (41% were
preterm infants). They defined right atrial thrombosis as
high-risk if thrombosis was large, pedunculated, mobile,
or snake-shaped and mobile. A significant difference in
mortality was found between the high-risk group (16,7%;
3 of 18) and the low-risk group (0%; 0 of 32) [8].
The NEOCLOT working group has refined the ACCP
recommendations into a more detailed guideline based
on the scarce data and expert opinion in order to
standardize treatment of neonatal CVC-thrombosis na-
tionally. For the management of neonatal CVC-
thrombosis a distinction was made between CVC-
thrombosis located in a blood vein (non-occlusive versus
occlusive) and CVC-thrombosis located in the right
atrium. Furthermore, high-risk (life-threatening) throm-
bosis was defined (Figs. 1 and 2). In the NEOCLOT
study, evaluation of this new guideline will be per-
formed. This article describes the study protocol of the
NEOCLOT study.
Methods/design
Aim of the study
The primary aim of the NEOCLOT study is to evaluate
the efficacy and safety of the management of
CVC-thrombosis in neonates as advised in the national
guideline for neonatal CVC-thrombosis. Secondary aims
include the evaluation of risk factors for neonatal
CVC-thrombosis, the adherence to the guideline and the
frequency of chronic complications of neonatal
CVC-thrombosis after 1 year of follow-up.
Study design and setting
The NEOCLOT study is a multi-center prospective
observational cohort study conducted in all 10 neonatal
intensive care units (NICUs) in the Netherlands. The in-
clusion period will be at least 5 years. All patients will be
followed for a minimum of 1 year. The Medical Ethics
Review Committee confirmed that official approval of
this study was not required as the Medical Research
Involving Human Subjects Act did not apply to the
NEOCLOT study. (#14.17.0121).
Study population
Inclusion criteria
All preterm and term infants (0-6 months) admitted
on one of the NICUs with CVC-thrombosis will be
included.
Diagnosis of CVC-thrombosis
Symptoms of neonatal CVC-thrombosis include
swelling, erythema, skin discoloration, increased
warmth, pain, and/or tenderness of the affected arm
or leg, venous distension, presence of subcutaneous
collateral veins, superior vena cava syndrome, loss of
central venous catheter patency, prolonged catheter-
related septicaemia, unexplained thrombocytopenia,
arrhythmia and hemodynamic instability [19]. Symptomatic
CVC-thrombosis has to be confirmed by Doppler
ultrasonography. CVC-thrombosis is diagnosed via
ultrasonography if a non-compressible segment of a vein,
Fig. 1 CVC-thrombosis in a blood vein
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absence of flow, or an echogenic intraluminal thrombus is
present.
CVC-thrombosis in a vein is defined as a non-
obstructive clot if blood flow is still present and as an
obstructive clot if blood flow is absent. High-risk CVC-
thrombosis in veins is defined as thrombosis which com-
promises an organ or limb. High-risk thrombosis in the
right atrium is defined as thrombosis, which 1) restricts
the outflow from the right atrium via the tricuspid
valve, 2) extends via the tricuspid valve or patent for-
amen ovale, 3) causes severe arrhythmias, 4) causes
hemodynamic instability, 5) is pedunculated, mobile, or
snake-shaped and mobile, and 6) grows despite ad-
equate therapeutic heparin levels.
Treatment of patients
In all neonates with CVC-thrombosis, it is advised to re-
move the CVC, if possible.
Treatment of CVC-thrombosis is divided into treat-
ment of CVC-thrombosis in veins and CVC-thrombosis
in the right atrium. In both scenarios, it is necessary to
establish whether the thrombosis is deemed high-risk. In
addition, the risks and benefits of all treatment options
versus risks of ongoing thrombosis should be considered
in each neonate before treatment is started. Relative
contraindications for anticoagulation and thrombolysis
include invasive surgical procedure(s) in the preceding
10 days, intracranial bleeding in the preceding 10 days,
invasive surgical procedure(s) scheduled within 3 days,
active bleeding, severe asphyxia, very preterm neonates
(< 28 weeks) with high risk of intraventricular haemor-
rhage and severe thrombocytopenia.
CVC-thrombosis in a blood vein
Figure 1 shows the consensus-based algorithm regarding
the proposed policy to CVC-thrombosis in a blood vein.
High-risk CVC-thrombosis should be treated with
thrombolytic therapy followed by anticoagulant therapy
for at least 4 to 6 weeks. During thrombolysis ultrason-
ography will be performed once daily (see Table 1).
After cessation of thrombolysis, LMWH should always
be started. After 4 to 6 weeks, ultrasonography will be
performed. If the clot has disappeared, anticoagulation
will be stopped.
Fig. 2 CVC-thrombosis in the right atrium
Table 1 Thrombolytic therapy
Thrombolytic
agent
Therapeutic dose Monitoring
r-TPA Start: 0.1 mg/kg/h iv
Continuous infusion
for longer
periods with
increasing doses if
no improvement
Max. dose: 0.5 mg/
kg/h iv
Check CBC, APTT, PT, fibrinogen,
D-dimers daily
Exclude ICH by US daily
Transfuse with FFP daily
Maintain fibrinogen > 1.0 g/L and
platelets > 50 × 109/L
Check thrombus resolution once
to twice daily
Abbreviations: r-TPA recombinant tissue plasminogen activator, h hour, iv
intravenously, CBC complete blood count, APTT activated partial
thromboplastin time, PT prothrombin time, ICH intracranial hemorrhage,
US ultrasound, FFP Fresh frozen plasma, max maximum
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For non-obstructive CVC-thrombosis, a “wait and see”
policy is recommended, with Doppler ultrasonography
follow-up within 5 days, depending on the size of throm-
bosis. If the size of thrombosis increases, anticoagulant
therapy should be started. In all neonates with obstruct-
ive CVC-thrombosis and without indication for thromb-
olysis, anticoagulant therapy (LMWH) should be started
immediately.
CVC-thrombosis in the right atrium
Figure 2 shows the consensus-based algorithm regarding
the proposed policy to CVC-thrombosis in the right
atrium. If thrombosis in the right atrium is defined as
high-risk and there are no contraindications for thrombo-
lytic therapy, thrombolysis should be administrated as
soon as possible. After cessation of thrombolysis, LMWH
should always be started. After 4 to 6 weeks of LMWH,
ultrasonography will be performed. If the clot has disap-
peared, anticoagulation will be stopped.
A “wait and see” policy is recommended for CVC-
thrombosis in the right atrium obstructing less than
half of the atrium and without indication for thromb-
olysis. Echocardiographic follow-up of these thrombi
should be performed every 1 to 3 days, depending on
the size of thrombosis. If thrombosis extends during
the “wait and see” policy, anticoagulant therapy
should be started. If CVC-thrombosis fills more than
half of the right atrium and has no indication for
thrombolytic therapy, anticoagulant therapy (LMWH)
should be started immediately.
Anticoagulant and thrombolytic therapy
The working group prefers r-tPA above urokinase and
streptokinase due to assumed increased affinity for
fibrin-bound plasminogen. Table 1 shows the protocol
for thrombolysis with r-tPA.
LMWH is preferred above UFH due to reduced need
of monitoring, potential decreased risk of bleeding and
the greater customisability in the Netherlands. Table 2
shows the LMWH protocol.
When LMWH is administered via a subcutaneous port
(Insuflon©), it is important to check the injection site and
to change the port at regular intervals, especially in neo-
nates with little subcutaneous fat. Alternatively, one can
refrain from using such a port. Platelet transfusions are
not encouraged when thrombocytopenia is present as
these transfusions may contribute to extension of throm-
bosis. Alternatively, dosage of LMWH may be reduced to
prophylactic dose, depending on size of thrombosis, risk
of embolization and duration of previous treatment
period. The maximum duration of antithrombotic therapy
in neonatal CVC-thrombosis is 3 months. If at an earl-
ier stage ultrasonography shows that thrombosis has re-
solved, antithrombotic therapy can be stopped. Ideally
these ultrasounds are performed at 6 weeks. However,
when a child is discharged before 6 weeks, an ultra-
sound will be performed earlier.
Outcome measures
Outcomes of primary aims
The primary efficacy outcome for the NEOCLOT study
is a composite outcome consisting of recurrent throm-
bosis and death due to CVC-thrombosis after start of
management of CVC-thrombosis. The primary safety
outcome is the incidence of major bleedings during
thrombolytic and anticoagulant therapy.
Major bleeding is defined as reported by Mitchell et al.:
1) fatal bleeding, 2) clinically overt bleeding associated with
a decrease in hemoglobin of at least 20 g/L (i.e., 2 g/dL or
1.24 mmol/L) in a 24-h period, (3) bleeding that is retro-
peritoneal or pulmonary, or (4) bleeding that requires sur-
gical intervention in an operating room [20]. Intracranial
bleeding is categorized major bleeding as defined by Curley
et al. in the Planet-2 study: Intraventricular haemorrhage
(IVH) (H1, H2 or H3) with ventricular dilatation, IVH (H1,
H2, H3) with parenchymal extension, any evolution of
intracranial haemorrhage from IVH or germinal layer hea-
morrhage to IVH with ventricular dilatation or IVH with
parenchymal extension [21].
The secondary efficacy outcomes are the individual
components of the primary outcome, i.e. death due to
CVC-thrombosis and recurrent thrombosis and all-cause
mortality. The secondary safety outcomes include clinic-
ally relevant non-major bleeding (CRNMB) and minor
bleedings during fibrinolytic and anticoagulant therapy as
defined by Mitchell et al. [20]. All intracranial bleedings
which are not defined as major bleeding will be catego-
rized as non-major intracranial bleeding. CRNMB is a
composite of (1) overt bleeding for which a blood product
is administered and not directly attributable to the
patient’s underlying medical condition and (2) bleeding
that requires medical or surgical intervention to restore
hemostasis, other than in an operating room. Minor
bleeding is defined as any overt or macroscopic evidence
Table 2 Anticoagulant therapy [4, 11, 13]
LMWH Therapeutic dose Monitoring
Nadroparin
0 – 2 m
Enoxaparin
0 – 2 m
Dalteparin
0 – 2 m
Tinzaparin
0 – 2 m
120-150 U/kg/12 h sc
1,7 mg/kg/12 h sc in
preterm neonates
1,5 mg/kg/12 h sc in
term neonates
150 U/kg/12 h sc
275 U/kg/24 h sc
Check anti-FXa level 4 h
after 2nd dose;
Target anti-FXa level: 0.5–1.0 U/mL
Check platelets regularly
Abbreviations: LMWH low-moleculair-weight heparin, h hour, m months,
sc subcutaneously
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of bleeding that does not fulfil the above criteria for either
major bleeding or CRNMB.
Outcomes of secondary aims
Outcomes of the secondary aims consist of frequency of
risk factors for CVC-thrombosis, frequency of protocol
variations and frequency and severity of long-term con-
sequences after 1, 2 and 5 years, including post throm-
botic syndrome (PTS) and residual thrombosis.
Data collection
Data from all neonates with CVC-thrombosis will be
added to the Good Clinical Practice proof web-based
NEOCLOT database. This database is only accessible for
the participating investigators. Security is guaranteed
with login names, login codes and encrypted data trans-
fer. Data of all patients will be coded and the key to this
coding is only known to the local investigator.
The following data will be collected in the web-based
NEOCLOT database:
– Baseline characteristics: gestational age, birth weight,
gender, Apgar score at 5 min, mechanical ventilation
at time of diagnosis
– Characteristics of CVC-thrombosis: date, location,
diagnostic method, symptoms, size, occlusive or
non-occlusive, high-risk or low-risk thrombosis
– Potential risk factors for CVC-thrombosis: type of
CVC, size of CVC, number of attempted CVC
insertions, number of lumens, place of insertion of
CVC, location of catheter tip, CVC-days, CVC-in-
fection according to the National Healthcare Safety
Network criteria [22], suspected CVC-infection,
polycythaemia (venous haematocrit above 0.65 L/L),
the presence of disseminated intravascular coagula-
tion [23], shock (hypotension, needing therapy), con-
genital heart disease, recent surgery, family history
of thrombophilia, and maternal problems including
maternal diabetes and antiphospholipid syndrome.
– Treatment of CVC-thrombosis: applied policy,
catheter removal, duration and dosages of
thrombolytic and anticoagulant therapy, effect of
applied policy, and complications of therapy,
including bleeding complications.
– Follow-up: death due to thrombosis or other reason,
pulmonary embolism, stroke, recurrent thrombosis,
and residual thrombosis after end of therapy.
Residual thrombosis will be determined by using
Doppler ultrasonography until thrombosis has
disappeared. PTS will be assessed at the NICU
outpatient follow-up clinic after 1, 2 and 5 years
according to the modified Villalta score [24]. At
5-years follow-up the new developed CAPTSureTM
will be used, as well [25].
Statistical analysis
Sample size calculation
The most important safety outcome of this prospective
observational study is major bleeding. In the literature
the mean prevalence of major bleeding in neonates with
antithrombotic agents is about 10%. With this national
guideline we expect the effect on the outcome of major
bleeding in all neonates, to decline from 10 to 5%. Given
that we have 150 neonates, the 95% CI will be about 2.5
to 9.9%, which means that we have a large probability of
a significant difference with the literature. The formula
for the CI is based on the binomial distribution for inde-
pendent cases.
Baseline data will be analysed by descriptive statistics.
Data will be presented as mean and standard deviations or
medians and ranges depending on their distribution. The
proportion of patients who developed the primary and
secondary outcomes will be shown. Continuous variables
will be analysed using Student’s t test or Mann-Whitney
test. Categorical data will be analysed using chi-square test
or Fisher exact test. The proportion of patients with
various risk factors for CVC-thrombosis will be calculated.
The significance level is set at p < 0.05. Data will be
analysed using PASW Statistics (SPSS) 20.0.
Discussion
Advances in medical and surgical management has im-
proved survival of sick (preterm) neonates, but has caused
an increased incidence of thrombo-embolic complications.
Lack of prospective clinical trials of antithrombotic treat-
ment in (preterm) neonates leads to extrapolation of re-
sults of adult management studies to children. However,
extrapolation of adult results to (preterm) neonates is
difficult due to differences between neonatal and adult
hemostasis and the presence of severe underlying medical
conditions increasing the risk of bleeding complications in
these vulnerable infants [26].
Furthermore, natural history of neonatal thrombosis
seems to differ from that of adult thrombosis, as about
50% of neonatal thrombi appears to vanish without anti-
coagulant therapy. Determination of the natural history of
neonatal thrombosis and identification of these “non-
risky” thrombi is important to safely withhold anticoagula-
tion in future patients.
As result of the national guideline, antithrombotic
treatment of neonatal CVC-thrombosis has become
identical on all NICUs in the Netherlands. Prospective
collection of the neonates treated according to the
protocol will enable evaluation of the used management
strategy and generate data that can be used in follow-up
treatment studies. For example, the NEOCLOT study
allows investigating the natural history of specific neo-
natal catheter-related clots. In the current guideline
“non-risky” thrombi were defined as non-obstructive
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thrombi in veins and thrombi filling less than 50% of the
right atrium. Wait and see policy is applied to these
thrombi. Results of the NEOCLOT study will show
whether it will be safe to withhold anticoagulation in
neonates with these thrombi.
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